Sep 2, 2019
|
Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study
|
Aug 9, 2019
|
Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights
|
May 30, 2019
|
Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference
|
May 7, 2019
|
Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights
|
Mar 14, 2019
|
Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors
|
Mar 7, 2019
|
Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
|
Mar 6, 2019
|
Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights
|
Feb 21, 2019
|
Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference
|
Feb 7, 2019
|
Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
|
Nov 13, 2018
|
Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C
|